Effect of the cessation of long-term hormone replacement therapy on plasma plasminogen activator inhibitor-1 and fibrinogen

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 125, Issue 2, 2006, Pages 217-220

  Kalela, Anne ^a   Jokela, Hannu ^b   Lehtimäki, Terho ^b   Uppa, Helena ^b   Kunnas, Tarja ^a   Teisala, Klaus ^b   Punnonen, Reijo ^b   Nikkari, Seppo T ^a,b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Fibrinogen; Hormone replacement therapy; Plasminogen activator inhibitor 1

Indexed keywords

ESTRADIOL VALERATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; LONG TERM CARE; NORMAL HUMAN; PLASMINOGEN ACTIVATION; POSTMENOPAUSE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33645885915     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2005.10.010     Document Type: Article

References (28)

1. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., and Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Int Med 133 (2000) 933-941
2. Grodstein F., Stampfer M.J., Falkeborn M., Naessen T., and Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 10 (1999) 476-480
3. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
4. Grady D., Herrington D., Bittner V., et al., HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288 (2002) 49-57
5. Manson J.E., Hsia J., Johnson K.C., et al., Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
6. Huber K., Resch I., Stefenelli T., et al. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb Haemost 63 (1990) 336-339
7. Gebara O.C.E., Mittleman M.A., Sutherland P., et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study. Circulation 91 (1995) 1952-1958
8. Shahar E., Folsom A.R., Salomaa V.V., et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Circulation 93 (1996) 1970-1975
9. Schneider D.J., Taatjes D.J., Howard D.B., and Sobel B. Increased reactivity of platelets induced by fibrinogen independent of ist bindings to the IIb-IIIa surface glycoprotein. A potential contributor to cardiovascular risk. J Am Coll Cardiol 33 (1999) 261-266
10. Herrick S., Blanc-Brude O., Gray A., and Laurent G. Fibrinogen. Int J Biochem Cell Biol 31 (1999) 741-746
11. Meade T.W., Mellows S., Brozovic M., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet 2 (1986) 533-537
12. Kannel W.B., Wolf P.A., Castelli W.P., and D'Agostino R.B.D. Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA 258 (1987) 1183-1186
13. Yarnell J.W., Baker I.A., Sweetnam P.M., et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 83 (1991) 836-844
14. Angerer P., Störk S., Kothny W., Schmitt P., and von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 21 (2001) 262-268
15. Lobo R.A., Bush T., Carr B.R., and Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76 (2001) 13-24
16. Scarabin P.Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., and Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 17 (1997) 3071-3078
17. Vehkavaara S., Silveira A., Hakala-Ala-Pietila T., et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85 (2001) 619-625
18. Nickelsen T., Creatsas G., Rechberger T., et al., Euralox 1 Study Group. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 4 (2001) 320-331
19. Perry W., and Wiseman R.A. Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, haematology and biochemistry. Maturitas 42 (2002) 157-164
20. Koh K.K., Mincemoyer R., Bui M.N., et al., Cannon III R.O. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336 (1997) 683-690
21. Andersen L.F., Gram J., Skouby S.O., and Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol 180 (1999) 283-289
22. Borgfeldt C., Li C., and Samsioe G. Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. Climacteric 7 (2004) 78-85
23. Dapper D.V., and Didia B.C. Haemorheological changes during the menstrual cycle. East Afr Med J 79 (2002) 181-183
24. Bo M., Raspo S., Morra F., Cassader M., Isaia G., and Poli L. Body fat is the main predictor of fibrinogen levels in healthy non-obese men. Metabolism 53 (2004) 984-988
25. Nabulsi A.A., Folsom A.R., White A., et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328 (1993) 1069-1075
26. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI Trial. JAMA 273 (1995) 199-208
27. Nozaki M., Ogata R., Koera K., Hashimoto K., and Nakano H. Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy. Climacteric 2 (1999) 124-130
28. Yilmazer M., Fenkci V., Fenkci S., et al. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. Maturitas 46 (2003) 245-253